secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001104659-23-023522
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx BeAT-HF trial misses primary endpoint; positive secondary analyses support Barostim label expansion plan
--------------------------------------------------------------------------------

- Trial of 323 HFrEF patients did not reach statistical significance on primary composite endpoint of CV mortality and HF morbidity.
- Prespecified analyses favored Barostim: all-cause survival free from LVAD/transplant, Win Ratio analysis, clinical stability.
- Safety and symptomatic improvement at 6 months durable through 24 months.
- Company plans to submit totality of evidence to FDA for expanded Barostim labeling.
- Data to be presented at THT conference on March 21, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923023522/0001104659-23-023522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923023522/tm237383d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-023522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer